| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Business Officer
1 company
Pierre Beaurang last filed a Form 4 in August 2021, as Chief Business Officer at NRIX. Pierre Beaurang's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Pierre Beaurang's trades have earned a middling insider score of 64/100 across 5 rated trades. Over a 12-month horizon, all 5 of those trades were profitable, with an average 12-month return of +49.6%.
At the last filing, the largest reported position was 4,330 shares of NRIX. The NRIX filings lean toward selling, a net 60,000 shares.
Pierre Beaurang has 9 Form 4 filings on record from February 2021 to August 2021, all as Chief Business Officer at Nurix Therapeutics (NRIX), 2021.
The 33 reported transactions were 21 open-market sales, 11 option exercises and 1 option or other derivative award.
Counted by filing, the open-market trades come to no purchases and 7 sales worth about $1.8M.
The largest open-market sale was 15,000 shares of NRIX at an average $35.49 on February 18, 2021, about $532K.
Shares as reported in the last Form 4 for each company; the most recent is from August 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Business Officer | Sale+OE | 7,500 | $29.86 | $223,925.93 | -63.4% | +10.2% | -34.7% | |
| Jul 12, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Business Officer | Sale+OE | 7,500 | $23.92 | $179,418.70 | -63.4% | +17.2% | -33.2% | |
| Jun 10, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Business Officer | Sale+OE | 7,500 | $29.37 | $220,248.49 | -63.4% | +20.6% | -65.4% | |
| May 10, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Business Officer | Sale+OE | 7,500 | $26.49 | $198,644.22 | -63.4% | +15.2% | -64.8% | |
| Apr 12, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Business Officer | Sale+OE | 7,500 | $27.28 | $204,631.89 | -63.4% | -10.2% | -50.0% | |
| Mar 8, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Business Officer | Sale+OE | 7,500 | $37.02 | $277,678.49 | - | - | - | |
| Feb 18, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Business Officer | Sale+OE | 15,000 | $35.49 | $532,351.76 | - | - | - |